# Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

> **NCT01259102** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Buprenorphine transdermal patch

## Key facts

- **NCT ID:** NCT01259102
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2001-03
- **Final completion:** 2001-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259102, "Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01259102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*